Friday, February 27, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC ‘starting to see mix-and-match data’ for COVID-19 vaccines

With the Pfizer (PFE)/BioNTech (BNTX) booster guidance in the rearview mirror, the CDC and the country’s other regulatory and public health agencies are gearing up to tackle Moderna’s (MRNA) and eventually Johnson & Johnson’s (JNJ) booster filings for recipients of those vaccines.

Meanwhile, many have wondered why the U.S. is not following Europe’s and Canada’s lead in allowing mixing and matching of vaccine brands in order to be considered fully vaccinated or for booster doses.

CDC Director Dr. Rochelle Walensky told that information is not too far away.

“We’re starting to see some of the mix-and-match data,” she said, noting that studies are already underway.

“As soon as we have those data to present, both to the FDA and to the CDC, we’ll have recommendations there as well,” Walensky said.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said Tuesday the first batch of data pertains to Moderna as a booster for either the J&J or Pfizer vaccines.

That data is available now, and data from trials of the other two vaccines as mixed boosters are forthcoming in the next month.

Source: Yahoo Finance

https://finance.yahoo.com/news/cdc-starting-to-see-mix-and-match-data-for-covid-19-vaccines-director-131034795.html

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!